ConductScience.org, home

Paper5051663

Results of treatment of malignant tumors with ftorafur.

Blokhina NG and 2 others. Cancer, 1972. Cited by 115 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Results of treatment of malignant tumors with ftorafur. Papers, record 5051663. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/5051663

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Results of treatment of malignant tumors with ftorafur.
PubMed
Journal
Cancer
PubMed
Year
1972
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
115
iCite
Relative citation ratio, by iCite
4.6
iCite
Revised in PubMed
2019-06-20
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Blokhina NGN G
2Vozny EKE K
3Garin AMA M

Source PubMed

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
FluorouracilMajor topic
NeoplasmsMajor topic
Antimetabolites
Antineoplastic Agents
Brain Neoplasms
Breast Neoplasms
Colonic Neoplasms
Deoxyribonucleosides
Furans
Humans
Oligodendroglioma
Pyrimidines
Rectal Neoplasms
Stomach Neoplasms
USSR

Source PubMed

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 115 citations.

PMIDTitleJournalYearIn PapersSource
26,396,765Crystal structures of 4-phenyl-piperazin-1-ium 6-chloro-5-ethyl-2,4-dioxopyrimidin-1-ide and 4-phenyl-piperazin-1-ium 6-chloro-5-isopropyl-2,4-dioxopyrimidin-1-ide.Acta Crystallogr E Crystallogr Commun2015https://conductscience.org/library/papers/26396765PubMed
24,764,9664-(2-Meth-oxy-phen-yl)piperazin-1-ium 6-chloro-5-isopropyl-2,4-dioxopyrimidin-1-ide.Acta Crystallogr Sect E Struct Rep Online2014https://conductscience.org/library/papers/24764966PubMed
11,122,822Novel oral chemotherapy agents.Curr Oncol Rep2000https://conductscience.org/library/papers/11122822PubMed
10,510,136A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.Br J Clin Pharmacol1999https://conductscience.org/library/papers/10510136PubMed
10,363,582p53 status predicts the efficacy of postoperative oral administration of tegafur for completely resected non-small cell lung cancer.Jpn J Cancer Res1999https://conductscience.org/library/papers/10363582PubMed
9,744,503Induction of apoptosis in human tumour xenografts after oral administration of uracil and tegafur to nude mice bearing tumours.Br J Cancer1998https://conductscience.org/library/papers/9744503PubMed
8,398,696In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis.Br J Cancer1993https://conductscience.org/library/papers/8398696PubMed
7,623,069Clinical application of 18F-FUdR in glioma patients--PET study of nucleic acid metabolism.J Neurooncol1995https://conductscience.org/library/papers/7623069PubMed
6,813,336Chemotherapeutic studies on N-nitrosoacetoxymethyl-methylamine-and 1,2-dimethylhydrazine-induced colonic tumors in rats: monotherapy with 5-fluorouracil, ftorafur, CGP 6809, and CGP 15'720A.J Cancer Res Clin Oncol1982https://conductscience.org/library/papers/6813336PubMed
6,792,409Comparative efficacy of antitumor treatment for liver metastases from colorectal cancer.Jpn J Surg1981https://conductscience.org/library/papers/6792409PubMed
6,182,702Palliative and adjunctive measures in rectal cancer.World J Surg1982https://conductscience.org/library/papers/6182702PubMed
3,090,050Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine.J Cancer Res Clin Oncol1986https://conductscience.org/library/papers/3090050PubMed
3,032,726Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma.Gastroenterol Jpn1987https://conductscience.org/library/papers/3032726PubMed
2,257,207Phase II trial of UFT in advanced colorectal and gastric cancer.Br J Cancer1990https://conductscience.org/library/papers/2257207PubMed
2,109,630Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study.Br J Cancer1990https://conductscience.org/library/papers/2109630PubMed
1,760,854Antitumor activity of FTC-092, a masked 5-trifluoromethyl-2'-deoxyuridine derivative.Cancer Chemother Pharmacol1991https://conductscience.org/library/papers/1760854PubMed
589,882Pharmacokinetics of 5-fluorouracil: inter-relationship with biochemical kinetics in monitoring therapy.Clin Pharmacokinet1977https://conductscience.org/library/papers/589882PubMed
155,503New drugs under clinical evaluation in the United States.Cancer Chemother Pharmacol1978https://conductscience.org/library/papers/155503PubMed
119,584Ftorafur: a self-limiting source of 5-fluorouracil?Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/119584PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/5051663

GET https://conductscience.org/api/papers/v1/5051663/authors